Mukka Proteins (MUKKA)

FairStock Score: 52/100 — MIXED

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding at 73.33% aligns management interests with minority shareholders.
• Sales growth of 115.57% reflects strong revenue momentum and demand.
• P/E of 15.26 and P/B of 1.94 are moderate, not extreme overvaluation.
• Latest quarter shows positive operations with sales ₹654 Cr and net profit ₹27 Cr.
• Book value of ₹12.33 provides some downside reference near current price.

Concerns

• Profit fell 9.56% despite 115.57% sales growth, indicating severe margin compression.
• Debt/equity of 1.32 is elevated, adding financial risk if profits weaken.
• Piotroski F-Score of 4/9 suggests weak fundamental health.
• Zero dividend yield means investors receive no income while waiting.

AI Analysis

At first glance, Mukka Proteins looks like a classic value play: a P/E of 15.26 and a P/B of 1.94, with promoters holding 73.33%, so owners have skin in the game. But Graham taught me to look behind the multiple. Sales jumped 115.57%, yet profit fell 9.56%. That tells me this is a business that can move huge volumes without retaining the benefits — a classic commodity margin squeeze. The latest quarter sales of ₹654 Cr produced only ₹27 Cr in net profit, a thin 4.1% margin. With debt/equity at 1.32, the balance sheet adds risk; elevated leverage can punish shareholders when margins compress. ROE of 9.99% and ROCE of 11.59% are acceptable, but not the kind of extraordinary returns I search for. The Piotroski F-score of 4/9 reinforces my caution: the underlying fundamentals are tepid, and zero dividend means I'm not being paid to wait. Price is not cheap enough to compensate for these issues. At ₹23.97, the market cap is ₹683 Cr; book value ₹12.33 gives some floor, but I'm not buying a stock merely because it trades at a discount to its own history. The 52-week range shows recent price weakness, and that can be an opportunity only if the business quality is intact. Here, profit direction is wrong. A PEG of 0.13 might tempt growth investors, but with actual profit growth negative, that metric is misleading. This looks more like a cyclical animal-feed commodity business than a franchise with durable pricing power. I would need stronger margins and lower debt before considering an entry.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer